Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
45.28
+0.49 (1.09%)
Feb 6, 2026, 4:00 PM EST - Market closed
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Crinetics Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $75.78, which forecasts a 67.36% increase in the stock price over the next year. The lowest target is $52 and the highest is $105.
Price Target: $75.78 (+67.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Crinetics Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 2 | 2 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 11 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $67 | Hold → Strong Buy | Upgrades | $67 | +47.97% | Jan 12, 2026 |
| Citizens | Citizens | Buy Maintains $108 → $105 | Buy | Maintains | $108 → $105 | +131.89% | Jan 8, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $77 → $80 | Buy | Maintains | $77 → $80 | +76.68% | Jan 6, 2026 |
| Citizens | Citizens | Buy Maintains $143 → $108 | Buy | Maintains | $143 → $108 | +138.52% | Nov 7, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $73 → $87 | Buy | Maintains | $73 → $87 | +92.14% | Sep 30, 2025 |
Financial Forecast
Revenue This Year
6.23M
from 1.04M
Increased by 499.13%
Revenue Next Year
61.82M
from 6.23M
Increased by 893.14%
EPS This Year
-5.05
from -3.69
EPS Next Year
-5.15
from -5.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 10.0M | 118.2M | ||||
| Avg | 6.2M | 61.8M | ||||
| Low | 3.6M | 20.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 863.6% | 1,798.3% | ||||
| Avg | 499.1% | 893.1% | ||||
| Low | 249.0% | 225.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.08 | -2.98 | ||||
| Avg | -5.05 | -5.15 | ||||
| Low | -5.07 | -6.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.